Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1343342

registered interest
date	02/07/2021
answering body	Home Office
answering dept id	1
answering dept short name	Home Office
answering dept sort name	Home Office
hansard heading	Drugs: Smuggling
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for the Home Department, pursuant to the Answer of 26 May 2021 to Question 5143, what evidence demonstrates that the arrests made have included high-level actors in the trafficking of controlled drugs; and how many of those arrested or charged in relation to Operation VENETIC have been convicted.
tabling member constituency	Reigate
tabling member printed	Crispin Blunt
uin	26080
answer	answer is ministerial correction date of answer 07/07/2021 answer text <p>The NCA reports that data derived from Operation VENETIC has, to date, led to over 2,300 people being arrested, over 1000 charged and 162 individuals convicted of a range of serious offences. These include well publicised cases of individuals involved in drug trafficking, like Thomas Maher, described by the judge at his trial as “an extremely important cog in the wheel of a sophisticated network”. A large number of cases linked to Operation VENETIC are progressing through the criminal justice system and it would be inappropriate to comment further on these at this time. The NCA regularly publishes the outcomes of investigations via press notices on its website.</p><p> </p> answering member constituency North West Hampshire answering member printed Kit Malthouse question first answered 07/07/2021 15:23:38 answering member 4495 label Biography information for Kit Malthouse
tabling member	104 label Biography information for Crispin Blunt

1343343

registered interest
date	02/07/2021
answering body	Home Office
answering dept id	1
answering dept short name	Home Office
answering dept sort name	Home Office
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for the Home Department, what the evidential basis is for cannabis-based products for medical use to be placed alongside fentanyl and diamorphine in Schedule 2 of the Misuse of Drugs Regulations 2001; and if she will make an assessment of the potential merits of placing such products in lower schedule such as Schedule 4.1 alongside Sativex.
tabling member constituency	Reigate
tabling member printed	Crispin Blunt
uin	26081
answer	answer is ministerial correction date of answer 07/07/2021 answer text <p>In February 2019, the then Home Secretary commissioned the ACMD to conduct a longer-term review of Cannabis-Based Products for Medicinal use (CBPM). The ACMD published their report on 27 November 2020 on gov.uk. In it they recommended:</p><p><em>“that the scheduling of CBPMs under Schedule 2 of the MDR remains appropriate and that no further legislative amendments to the MDR regarding CBPMs are required at this point in time.”</em></p><p>Unlike Sativex, most CBPM do not have a marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA). As such, in the absence of the reassurance that a CBPM has gone through the safety, quality and efficacy process established by the MHRA, it is right that it is in Schedule 2 of the Misuse of Drugs Regulations 2001. However, should a cannabis-based medicine receive a marketing authorisation from the MHRA, the Government will commission the Advisory Council on the Misuse of Drugs (ACMD) to reconsider the scheduling of the product under the Misuse of Drugs Regulations 2001. This was the case for Sativex following its marketing authorisation.</p> answering member constituency North West Hampshire answering member printed Kit Malthouse question first answered 07/07/2021 15:37:53 answering member 4495 label Biography information for Kit Malthouse
tabling member	104 label Biography information for Crispin Blunt